Prasugrel monotherapy versus standard DAPT in STEMI patients
with OCT-guided or angio-guided complete revascularisation:
design and rationale of the randomised, multifactorial COMPARE
STEMI ONE trial

J 2025

Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial

PARADIES, Valeria; Nicolas M Van MIEGHEM; Rohit M OEMRAWSINGH; Gert RICHARDT; Giovanni ESPOSITO et al.

Základní údaje

Originální název

Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial

Autoři

Vydání

Eurointervention, Toulouse, Europa edition, 2025, 1774-024X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Francie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 9.500 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00141494

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

antiplatelet therapy; optical coherence tomography; STEMI

Štítky

14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 4. 2026 09:59, Mgr. Tereza Miškechová

Anotace

V originále

Monotherapy with a potent P2Y12 receptor antagonist after 1 month of dual antiplatelet therapy (DAPT) may reduce bleeding in the absence of increased ischaemic events compared to 12-month DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). PCI guidance with optical coherence tomography (OCT) may enhance stent expansion. COMPARE STEMI ONE is an international, multicentre, open-label, randomised controlled trial. In 1,656 ST-segment elevation myocardial infarction (STEMI) patients, prasugrel monotherapy after 1 month of DAPT, as compared to standard 12-month prasugrel-based DAPT, will be tested for non-inferiority for the primary composite endpoint of net adverse clinical events-defined as all-cause death, myocardial infarction, stroke, or Bleeding Academic Research Consortium Type 3 or 5 bleeding events-at 11 months after randomisation. Furthermore, an ancillary substudy will test the superiority of OCT-guided versus angiography-guided staged complete revascularisation in achieving a larger minimal stent area (MSA) in non-culprit lesions during staged procedures. COMPARE STEMI ONE is the first randomised controlled trial assessing an abbreviated 1-month DAPT regimen followed by prasugrel monotherapy in the context of STEMI. The trial will also study the value of OCT-guided PCI in terms of the MSA of non-culprit lesions and may elucidate potential synergies between intravascular imaging-guided PCI and abbreviated DAPT regimens. (ClinicalTrials.gov: NCT05491200)

Citovat

PARADIES, Valeria; Nicolas M Van MIEGHEM; Rohit M OEMRAWSINGH; Gert RICHARDT; Giovanni ESPOSITO; Gianluca CAMPO; Francesco BURZOTTA; Paolo CANOVA; Axel LINKE; Italo PORTO; Daniela TRABATTONI; Koen TEEUWEN; Tom ADRIAENSSENS; Petr KALA; Goran STANKOVIC; van Vliet RIA; Daniele GIACOPPO; Joost DAEMEN a Pieter C SMITS. Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial. Eurointervention. Toulouse: Europa edition, 2025, roč. 21, č. 10, s. 571-580. ISSN 1774-024X. Dostupné z: https://doi.org/10.4244/EIJ-D-24-00829.

@article{2506928,
   author = {Paradies, Valeria and Mieghem, Nicolas M Van and Oemrawsingh, Rohit M and Richardt, Gert and Esposito, Giovanni and Campo, Gianluca and Burzotta, Francesco and Canova, Paolo and Linke, Axel and Porto, Italo and Trabattoni, Daniela and Teeuwen, Koen and Adriaenssens, Tom and Kala, Petr and Stankovic, Goran and Ria, van Vliet and Giacoppo, Daniele and Daemen, Joost and Smits, Pieter C},
   article_location = {Toulouse},
   article_number = {10},
   doi = {https://doi.org/10.4244/EIJ-D-24-00829},
   keywords = {antiplatelet therapy; optical coherence tomography; STEMI},
   language = {eng},
   issn = {1774-024X},
   journal = {Eurointervention},
   title = {Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial},
   url = {https://eurointervention.pcronline.com/article/prasugrel-monotherapy-versus-standard-dapt-in-stemi-patients-with-oct-guided-or-angio-guided-complete-revascularisation-design-and-rationale-of-the-randomised-multifactorial-compare-stemi-one-trial},
   volume = {21},
   year = {2025}
}

TY  - JOUR
ID  - 2506928
AU  - Paradies, Valeria - Mieghem, Nicolas M Van - Oemrawsingh, Rohit M - Richardt, Gert - Esposito, Giovanni - Campo, Gianluca - Burzotta, Francesco - Canova, Paolo - Linke, Axel - Porto, Italo - Trabattoni, Daniela - Teeuwen, Koen - Adriaenssens, Tom - Kala, Petr - Stankovic, Goran - Ria, van Vliet - Giacoppo, Daniele - Daemen, Joost - Smits, Pieter C
PY  - 2025
TI  - Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial
JF  - Eurointervention
VL  - 21
IS  - 10
SP  - 571-580
EP  - 571-580
PB  - Europa edition
SN  - 1774024X
KW  - antiplatelet therapy
KW  - optical coherence tomography
KW  - STEMI
UR  - https://eurointervention.pcronline.com/article/prasugrel-monotherapy-versus-standard-dapt-in-stemi-patients-with-oct-guided-or-angio-guided-complete-revascularisation-design-and-rationale-of-the-randomised-multifactorial-compare-stemi-one-trial
N2  - Monotherapy with a potent P2Y12 receptor antagonist after 1 month of dual antiplatelet therapy (DAPT) may reduce bleeding in the absence of increased ischaemic events compared to 12-month DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). PCI guidance with optical coherence tomography (OCT) may enhance stent expansion. COMPARE STEMI ONE is an international, multicentre, open-label, randomised controlled trial. In 1,656 ST-segment elevation myocardial infarction (STEMI) patients, prasugrel monotherapy after 1 month of DAPT, as compared to standard 12-month prasugrel-based DAPT, will be tested for non-inferiority for the primary composite endpoint of net adverse clinical events-defined as all-cause death, myocardial infarction, stroke, or Bleeding Academic Research Consortium Type 3 or 5 bleeding events-at 11 months after randomisation. Furthermore, an ancillary substudy will test the superiority of OCT-guided versus angiography-guided staged complete revascularisation in achieving a larger minimal stent area (MSA) in non-culprit lesions during staged procedures. COMPARE STEMI ONE is the first randomised controlled trial assessing an abbreviated 1-month DAPT regimen followed by prasugrel monotherapy in the context of STEMI. The trial will also study the value of OCT-guided PCI in terms of the MSA of non-culprit lesions and may elucidate potential synergies between intravascular imaging-guided PCI and abbreviated DAPT regimens. (ClinicalTrials.gov: NCT05491200)
ER  -

PARADIES, Valeria; Nicolas M Van MIEGHEM; Rohit M OEMRAWSINGH; Gert RICHARDT; Giovanni ESPOSITO; Gianluca CAMPO; Francesco BURZOTTA; Paolo CANOVA; Axel LINKE; Italo PORTO; Daniela TRABATTONI; Koen TEEUWEN; Tom ADRIAENSSENS; Petr KALA; Goran STANKOVIC; van Vliet RIA; Daniele GIACOPPO; Joost DAEMEN a Pieter C SMITS. Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial. \textit{Eurointervention}. Toulouse: Europa edition, 2025, roč.~21, č.~10, s.~571-580. ISSN~1774-024X. Dostupné z: https://doi.org/10.4244/EIJ-D-24-00829.

Přehled o publikaci